Skip to main content

Table 1 Patient characteristics in the “Pilot-TNBC” cohort

From: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

Pt ID Spec# 1 Spec# 2 Histology Age range Stage Lehmann subtypes (Neo)adjuvant chemo Radiation RFS (months) OS (months)
1 Breast Lung Met IDC 60–69 II BL2 → BL2 AC-T Yes 34 113
2 Breast Bone Met IDC 50–59 II LAR→LAR AC No 17 60
3 Breast LN Met IDC 40–49 II BL1 → BL1 AC No 39 92
4 LN Liver Met IDC 40–49 III BL1 → LAR Carbo/Taxol Yes 10 20
5 Breast Skin Met IDC 30–39 III M → M AC Unknown 2 9
6 Brain Soft tissue Met IDC 50–59 II M → M TAC No 31 67
7 Breast LN Met IDC 50–59 I BL1 → BL2 Declined No 26 46
8 Endometrium LN Met IDC 30–39 III M → LAR TC Unknown 11 58
9 Breast Contralateral breast Met ILC 40–49 II LAR→BL2 AC-T Yes 8 23
10 Breast Brain Met Metaplastic 50–59 II BL1 → BL1 AC-T Unknown 16 58
  1. IDC invasive ductal carcinoma, LN lymph node, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death), ILC invasive lobular carcinoma, AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide - > paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/cyclophosphamide, TC docetaxel /cyclophosphamide, Met metastatic tumor, BL1 basal-like 1, BL2 basal-like 2, M mesenchymal, LAR luminal androgen receptor, Spec specimen